MDA-MB-231, MDA-MB-453, HBC-4, HBC-5, MCF-7, BSY-1, ZR-75-1, and SKBR-3 breast cancer cell lines were maintained in RPMI-1640 containing 10% FBS and penicillin/streptomycin. HEK293 was maintained in Dulbecco’s modified Eagle medium containing 10% FBS and penicillin/streptomycin. Dasatinib was purchased from JS Research Chemicals Trading Co. Fluvastatin, doxorubicin, and paclitaxel were purchased from Wako Pure Chemicals. Geranylgeranyl diphosphate (GGPP), farnesyl diphosphate (FPP), GGTI-286, and FTI-276 were purchased from Sigma. MG-132 was purchased from Merck Mllipore, and pazopanib from ChemieTek.
Pazopanib
Manufactured by Chemietek
Pazopanib is a tyrosine kinase inhibitor. It functions by inhibiting various receptor tyrosine kinases involved in angiogenesis and cell proliferation.
Automatically generated - may contain errors
Lab products found in correlation
Paclitaxel, by Fujifilm (1 mentions)
Doxorubicin, by Fujifilm (1 mentions)
Fluvastatin, by Fujifilm (1 mentions)
Fti 276, by Merck Group (1 mentions)
Everolimus, by Selleck Chemicals (1 mentions)
Ethinyl estradiol, by Merck Group (1 mentions)
Midazolam, by Fujifilm (1 mentions)
Roxithromycin, by Merck Group (1 mentions)
Felodipine, by Merck Group (1 mentions)
Ranitidine hydrochloride, by Merck Group (1 mentions)
Fluvoxamine, by Merck Group (1 mentions)
Tadalafil, by Selleck Chemicals (1 mentions)
Cimetidine, by Merck Group (1 mentions)
Simvastatin, by Fujifilm (1 mentions)
Suvorexant, by Adooq (1 mentions)
Fluoxetine, by Merck Group (1 mentions)
2 protocols using pazopanib
1
Breast Cancer Cell Line Maintenance and Compound Treatment
2
Midazolam Metabolism and CYP3A Inhibition
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Midazolam was purchased from Wako Pure Chemical Industries (Osaka, Japan). The metabolite of Midazolam, 19-hydroxyMidazolam, was purchased from Sigma-Aldrich (St. Louis, MO). As an internal standard, 13 C-19-hydroxyMidazolam was obtained from Corning (Corning, NY). The following marketed drugs were used for the evaluation of the potential to inhibit or induce CYP3A: atomoxetine hydrochloride (Tokyo Chemical Industry, Tokyo, Japan), atorvastatin (LKT Laboratories, St. Paul, MN), azithromycin dehydrate (LKT Laboratories), casopitant mesylate (Santa Cruz Biotechnology, Dallas, TX), cimetidine (Sigma-Aldrich), deferasirox (Toronto Research Chemicals, North York, Canada), ethinyl estradiol (Sigma-Aldrich), everolimus (Selleck Chemicals, Houston, TX), felodipine (Sigma-Aldrich), fluoxetine (Sigma-Aldrich), fluvoxamine (Sigma-Aldrich), pazopanib (ChemieTek, Indianapolis, IN), ranitidine hydrochloride (Sigma-Aldrich), roxithromycin (Sigma-Aldrich), simvastatin (Wako Pure Chemical), suvorexant (AdooQ-BioScience, Irvine, CA), and tadalafil (Selleck Chemicals). Pooled human microsomes (mixed sex, 20 mg protein/ml) and pooled cryopreserved human hepatocytes were purchased from Sekisui XenoTech, LLC (Kansas City, KS). NADPH Regeneration System Solution A and NADPH Regeneration System Solution B were purchased from Corning.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!